Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 19/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.78 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.78 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.78 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.78 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.78 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15169901 | 1.00 | CCR5 (0.78) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL174296 | 1.00 | CCR5 (0.78) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL3876067 | 0.91 | CCR5 (0.84) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL12033051 | 0.91 | CCR5 (0.71) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL3874712 | 0.91 | CCR5 (0.84) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL15375694 | 0.91 | CCR5 (0.84) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL15375827 | 0.91 | CCR5 (0.84) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL2545806 | 0.90 | CCR5 (0.83) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL3874242 | 0.90 | CCR5 (0.71) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 | |
| SCHEMBL13915694 | 0.89 | CCR5 (0.69) | CCR5KCNH2CYP3A4ADRA2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779143-B2 | Crystalline forms of maraviroc phosphate and process for maraviroc amorphous form | HETERO RESEARCH FOUNDATION (IN) | 2014-07-15 | — | — | US | disclosed |
| US-20130211091-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | HETERO RESEARCH FOUNDATION (IN) | 2013-08-15 | — | — | US | disclosed |
| EP-2611446-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | Hetero Research Foundation (IN) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012029067-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | HETERO RESEARCH FOUNDATION (IN) | 2012-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130211091-A1 | CRYSTALLINE FORMS OF MARAVIROC PHOSPHATE AND PROCESS FOR MARAVIROC AMORPHOUS FORM | PNP, TYMP, SAMHD1 | CCR5 63/4885KCNH2 2796/4885CYP3A4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.